Raytheon awarded $71 million in Navy contracts for missile systems
Investing.com -- INmune Bio Inc. (NASDAQ:INMB) stock surged 28% after the company announced its Phase I/II trial of INKmune™ in metastatic castration-resistant prostate cancer (mCRPC) met both primary and secondary endpoints and is now closed to enrollment.
The clinical-stage immunology and inflammation company reported that INKmune™ demonstrated an excellent safety profile at all three dose levels tested in the "CaRe PC" trial, achieving the primary endpoint. Additionally, patients with low natural killer (NK) cell activation showed the greatest improvement in biomarkers of NK cell activation, helping define the target population for future trials.
"INKmune was safe and effective at activating NK cells in a subset of more than half of these patients with advanced disease," said Dr. Mark Lowdell, CSO at INmune Bio. "Excitingly we did see, in some patients, individual tumor lesions either reducing in size or completely disappearing during treatment, so we believe this could be evidence of a direct effect on tumor cell killing."
Following these positive results, INmune Bio plans to advance the program by designing a randomized Phase 2b trial in patients with less severe disease. This approach aims to enable more robust measurement of the drug’s effects and potential clinical benefits.
The company’s shares responded strongly to the announcement as investors appeared to welcome the positive trial results and advancement of the INKmune™ program.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.